ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0949

Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion

Toshihiko Komai1, Tomohisa Okamura2, Masanori Kono1, Kazuhiko Yamamoto3 and Keishi Fujio1, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan

Meeting: ACR Convergence 2023

Keywords: Animal Model, cytokines, interstitial lung disease, Systemic sclerosis, Transforming Growth Factor (TGF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We found that TGF-β3 regulates humoral immunity in a context-dependent manner [1]. Recent genome-wide association study reveals that TGF-β3 might be a novel target in African American systemic sclerosis (SSc) patients [2]. Since Tgfb3-/- mice die within 20 hours of birth [3], the physiological roles of TGF-β3 have not clearly elucidated. In this study, we evaluated the immunological and fibrotic roles of TGF-β3 by using mice with conditional Tgfb3 deletion.
[1] Komai T, et al. Front Immunol. 2018;9:1364., [2] Kaundal U, et al. ACR2022, Arthritis Rheumatol. 2022; 74 (suppl 9), [3] Kaartinen V, et al. Nat Genet. 1995;11(4):415-21.

Methods: TGF-β3 conditional knockout mice in CD4+ T cells (Tgfb3fl/flCD4Cre) and B cells (Tgfb3fl/flCD19Cre) were created. Histopathology, expression of fibrosis-related genes in lung by qRT-PCR in lungs, and flow cytometric analysis of splenocytes from these mice were conducted. Also, a continuous bleomycin infusion delivered by osmotic minipumps to these mice was conducted as an induced SSc model. To evaluate the effects of overexpression of TGF-β3, either pCAGGS-Mock, pCAGGS-Tgfb3 plasmid vectors were intravenously administered to lupus prone MRL/lpr mice with spontaneous interstitial pneumonia, and lung pathologies were assessed.In vitro, normal human lung fibroblasts (NHLFs) cultured with and without TGF-β3 were evaluated.

Results: Tgfb3fl/flCD4Cre mice developed inflammatory cell infiltration and fibrosis in lungs spontaneously (Figure 1A), and low-titer anti-dsDNA antibody production and increased marginal zone B cells was observed. The bleomycin-induction exacerbated interstitial pneumonia, and fibrosis-related genes of the lung tissue such as mCol1a1, mCol1a2, mSerpine1, and mSpp1 were up-regulated in both Tgfb3fl/flCD4Cre and Tgfb3fl/flCD19Cre mice in comparison to Tgfb3fl/flmice (Figure 1B). Further, the interstitial pneumonia of MRL/lpr mice was prone to be ameliorated by pCAGGS-Tgfb3 administration. In in vitro experiments, TGF-β3 inhibited the proliferation of NHLFs in a dose-dependent manner.

Conclusion: Our study suggested that TGF-β3 contributes to regulate systemic autoimmune and fibrotic responses. Anti-inflammatory and anti-fibrotic function of TGF-β3 might lead to future therapeutic target for interstitial pneumonia with autoimmune features.

Supporting image 1

Figure 1. Exacerbation of interstitial pneumonia by conditional Tgfb3 deletion.


Disclosures: T. Komai: Amgen, 6, Asahi Kasei, 6, Chugai, 5, 6, Daiichi-Sankyo, 6, Eisai, 6, Eli Lilly, 1, 6, GlaxoSmithKlein(GSK), 5, 6, Janssen, 6, Novartis, 6, Tanabe Mitsubishi, 6; T. Okamura: Chugai Pharmaceutical., 12, belong to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, supported by Chugai Pharmaceutical.; M. Kono: Asahi Kasei Pharma, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6; K. Yamamoto: AbbVie, 6, Pfizer Japan Inc, 12, Outsourcing contract, RegCell, 1, Sun Pharmaceutical Industries Ltd, 6; K. Fujio: AbbVie/Abbott, 6, Asahi Kasei, 5, 6, Astellas, 6, AstraZeneca, 6, Ayumi, 6, Bristol-Myers Squibb(BMS), 5, 6, Chugai Pharmaceutical., 5, 6, Daiichi-Sankyo, 6, Eisai, 5, 6, Eli Lilly, 5, 6, Janssen, 6, Novartis, 6, Ono, 6, Pfizer, 6, Sanofi, 6, Tanabe Mitsubishi, 5, 6, Tsumura, 5.

To cite this abstract in AMA style:

Komai T, Okamura T, Kono M, Yamamoto K, Fujio K. Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/development-of-interstitial-pneumonia-with-autoimmune-features-in-conditional-tgfb3-deletion/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-interstitial-pneumonia-with-autoimmune-features-in-conditional-tgfb3-deletion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology